lodged in the Uganda National Academy of Sciences, an
organization whose main mission is to advise the
government.
In addition to country-specific activities, GARP working
group members are regular participants in global discussions
on antibiotic resistance.
Moving forward
CDDEP is committed to maintaining GARP, expanding it and
strengthening the partnership. CDDEP researchers
continue to conduct innovative research on antibiotics and
antibiotic resistance globally, for example, a study that
quantified, for the first time since 1987, antibiotic
consumption in 63 countries between 2000 and 2010 (2)
and a call for global action in The Lancet Infectious Diseases (3).
In a move mirroring the development of GARP after work
in the United States, CDDEP has also begun constructing a
global version of Resistance Map (http://cddep.org/
projects/resistance-map), an interactive tool to explore the
evolution of antibiotic resistance in a set of pathogens over
time in North America and Europe.
Conclusion
GARP has succeeded in bringing a set of new voices to the
antibiotic resistance issue and to establishing local capacity
to develop and help to implement evidence-based policies in
eight LMICs. l
Acknowledgements
The author acknowledges support from the Graduate
Institute of International and Development Studies
(Geneva), the Royal Institute of International Affairs, the
Institute of Chatham House (London), and the Center for
Disease Dynamics, Economics & Policy.
Hellen Gelband is Associate Director for Policy at the Center for
Disease Dynamics, Economics & Policy (CDDEP). Her work spans
infectious disease, particularly malaria and antibiotic resistance,
and non-communicable disease policy, mainly in low- and middleincome
countries. Before joining CDDEP, then Resources for the
Future, she conducted policy studies at the (former) Congressional
Office of Technology Assessment, the Institute of Medicine of the
United States National Academies, and a number of international
organizations.
CONFRONTING ANTIMICROBIAL RESISTANCE
AMR CONTROL 2015 101
References
1.kusemererwa D, Kariuki S, Winters C, Braykov N, Megiddo I, Plant S, & Wesangula E.
(2013). Survey of antibiotic prices in public, private, and mission district-level hospitals in
Kenya. Pharmaceutical Journal of Kenya, 21(3), 208.
2.laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradi N and Cars O.
(2013). Antibiotic resistance-the need for global solutions. The Lancet Infectious Diseases,
13(12), 1057-98. doi:10.1016/S1473-3099(13)70318-9
3.van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, & Laxminarayan R.
(2014). Global antibiotic consumption 2000 to 2010: an analysis of national
pharmaceutical sales data. The Lancet Infectious Diseases, 3099(14), 1-9.
doi:10.1016/S1473-3099(14)70780-7